Filing Flows › ImmunityBio (IBRX) › Q2 2026
ImmunityBio (IBRX) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 4, 2026
ImmunityBio (IBRX) reported revenue of $51.2M for the second quarter 2026 (Q2 2026), +94% from a year earlier and +16% from the quarter before. Operating margin was -120.4%, net loss $230M (449.6% of revenue).
ImmunityBio, Q2 2026: revenue $51.2M (+94% year over year), operating margin -120.4%, net loss $230M, operating cash flow −$66.5M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $51.2M | +16% | +94% |
| Operating profit | −$61.7M | — | — |
| Net earnings | −$230M | — | — |
| Operating cash flow | −$66.5M | — | — |
What changed
Revenue was $51.2M in Q2 2026, up 94% year over year and up 16% from the previous quarter. Product revenue, net was the largest line at 99% of revenue. Product revenue, net added $24.3M year over year (up 92%), 98% of the total change.
Operating costs exceeded revenue by $61.7M, an operating margin of -120.4%. Total costs grew 16% against revenue growth of 94%. The fastest-growing cost line was Cost of revenue (+119%). The quarter ended with a net loss of $230.4M, narrower than the previous quarter's $632.8M loss. Net interest and other expense of $168.7M was the main reason.
Operating cash flow was −$66.5M. Non-cash charges added back $4.4M of depreciation and amortization and $8.5M of share-based compensation. Working capital and other items added $151.0M. Capital expenditures of $3.5M exceeded it, leaving free cash flow of −$70.0M.
Questions
What was ImmunityBio's revenue in the second quarter 2026?
ImmunityBio (IBRX) reported revenue of $51.2M for the second quarter 2026 (Q2 2026), +94% from a year earlier and +16% from the quarter before.
Was ImmunityBio profitable in the second quarter 2026?
Operating loss was $61.7M (-120.4% of revenue) and net loss $230M.
Source: ImmunityBio 10-Q on SEC EDGAR.